RPG Life Sciences Limited (NSE:RPGLIFE)

RPG Life Sciences Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 26, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	30,839	37,735	25,279	11,585	9,269	6,407
Market Cap Growth	-14.09%	49.27%	118.21%	24.98%	44.67%	128.15%
Enterprise Value	28,603	36,475	24,260	10,780	8,672	6,386
Last Close Price	1864.60	2259.00	1498.30	678.37	533.75	364.06
PE Ratio	15.22	20.59	28.84	17.13	18.01	16.02
PS Ratio	4.58	5.78	4.34	2.26	2.11	1.65
PB Ratio	5.57	7.11	6.74	3.77	3.62	2.96
P/TBV Ratio	5.78	7.43	7.29	4.22	4.19	3.57
P/FCF Ratio	-	90.21	100.59	19.94	22.72	12.88
P/OCF Ratio	-	48.47	26.79	12.76	14.32	11.00
EV/Sales Ratio	4.25	5.58	4.17	2.10	1.97	1.64
EV/EBITDA Ratio	19.80	22.78	19.08	10.53	10.25	9.34
EV/EBIT Ratio	23.88	26.17	21.84	12.24	12.26	11.90
EV/FCF Ratio	-	87.20	96.54	18.56	21.26	12.83
Debt / Equity Ratio	-	-	-	0	0.00	0.01
Debt / EBITDA Ratio	-	-	-	0.00	0.01	0.03
Debt / FCF Ratio	-	-	-	0	0.02	0.04
Net Debt / Equity Ratio	-0.40	-0.50	-0.34	-0.37	-0.27	-0.18
Net Debt / EBITDA Ratio	-1.55	-1.65	-0.99	-1.12	-0.81	-0.56
Net Debt / FCF Ratio	-	-6.33	-5.01	-1.98	-1.69	-0.77
Asset Turnover	-	1.12	1.25	1.34	1.36	1.37
Inventory Turnover	-	2.26	1.93	1.98	2.08	2.58
Quick Ratio	-	2.96	1.35	1.50	1.34	1.28
Current Ratio	-	3.88	2.28	2.57	2.58	2.21
Return on Equity (ROE)	-	40.48%	25.69%	24.01%	21.80%	20.36%
Return on Assets (ROA)	-	14.88%	14.89%	14.41%	13.65%	11.77%
Return on Invested Capital (ROIC)	29.51%	42.59%	37.41%	34.23%	27.27%	21.90%
Return on Capital Employed (ROCE)	-	25.90%	29.10%	27.80%	26.70%	24.00%
Earnings Yield	6.57%	4.86%	3.47%	5.84%	5.55%	6.24%
FCF Yield	-	1.11%	0.99%	5.01%	4.40%	7.77%
Dividend Yield	1.07%	0.89%	1.07%	1.77%	1.80%	1.98%
Payout Ratio	-	14.44%	22.64%	23.48%	23.14%	-
Total Shareholder Return	1.08%	0.89%	1.07%	1.77%	1.80%	1.98%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.